Veracyte Inc

VCYT is currently in a distribution phase with price forming sequential lower highs and lower lows under declining EMAs. The medium-term bias is Bearish with supply dominating demand, and short-term timing confirms bearish execution now on rallies into the 9/20 EMA zone. Execution should be Sell Now, as no pullback exhaustion is evident. Key risk is a mean-reversion bounce that holds above dynamic EMAs, invalidating the downtrend.

• ↑Q2 ’26 revenue $150.3M, +15% YoY driven by Decipher and Affirma demand
• ↑Full-year revenue guidance raised to $590–$596M, reflecting strong pipeline performance
• ↓Negative earnings yield indicates potential overvaluation and deters value investors